Tag: Amplyx

September 9, 2019 Off

Amplyx bags FDA fast track designation for two its antifungal candidates, for 7 indications

Amplyx was granted the FDA’s Fast Track designations for two of its lead antifungal candidate intravenous (IV) and oral formulations, fosmanogepix (APX001), for seven indications, the company said Monday ina press release.

August 2, 2017 Off

Arix supports Amplyx Pharmaceuticals with $67

By Dino Mustafić

Arix Bioscience has acquired an interest in Amplyx Pharmaceuticals – San Diego-based Amplyx is focused on developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections – as part of an oversubscribed $67 million Series C financing round.